Amgen and UCB have re-filed for FDA approval of osteoporosis drug romosozumab one year after the agency rejected a submission on safety grounds. The revised filing pools all the phase 3 data in a bid to show the sclerostin-targeting antibody has a positive risk-benefit profile.
Romosozumab looked well set to come to market when it aced its first phase 3 in September 2016. That changed in May 2017 when a second phase 3 detected a new cardiovascular safety signal. Two months later, the FDA rejected a filing for approval of romosozumab in postmenopausal women with osteoporosis.
Now, Amgen and UCB have gone back to the FDA. The new filing features data from the original, 7,180-person person phase 3 trial that formed the backbone of the original submission, plus results from two other studies.
One of the other studies is the second phase 3 of romosozumab in 4,093 postmenopausal women with osteoporosis who experienced a fracture. That clinical trial found romosozumab was better than alendronate at reducing fractures but also uncovered the safety signal. The third set of data included in the filing comes from a 245 person study of the effect of romosozumab in men.
Amgen and UCB are hoping that when the FDA gets to analyze all the safety and efficacy data it will conclude the benefits of romosozumab outweigh the risks. However, there remains a chance the FDA will turn the drug down or impose a restrictive label that limits its commercial prospects.
A restrictive label could see romosozumab struggle to live up to the blockbuster forecasts made by analysts prior to the safety scare. If romosozumab comes to market, it will face competition from Eli Lilly’s Forteo and Radius Health’s Tymlos. Romosozumab has some advantages over the competition, such as monthly dosing, but these could be swept away by cardiovascular safety concerns.
By: Nick Paul Taylor
Source: Fierce Biotech
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.